|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
 |
 |
 |
|
|||
 |
 |
Oncology Archives 1. Choi YB, Nicholas J. Autocrine and Paracrine
Promotion of Cell Survival and Virus Replication by Human Herpesvirus-8
Chemokines. J Virol. 2008 Apr 23. [Epub ahead of print] 2. Pratz K, Levis M. Incorporating FLT3 inhibitors
into acute myeloid leukemia treatment regimens. Leuk Lymphoma. 2008 May;49(5):852-63. 1. Gillison ML, D'Souza
G, Westra W, Sugar E, Xiao W, Begum S, Viscidi R. Distinct risk factor
profiles for human papillomavirus type 16-positive and human papillomavirus
type 16 negative head and neck cancers. J Natl Cancer Inst. 2008 Mar 11;
[Epub ahead of print] 2. Grossman SA, Olson J, Batchelor T, Peereboom
D, Lesser G, Desideri S, Ye X, Hammour T, Supko JG. Effect of phenytoin
on celecoxib pharmacokinetics in patients with glioblastoma. Neuro Oncol.
2008 Feb 20; [Epub ahead of print] 3. Laheru D, Lutz E, Burke J, Biedrzycki B, Solt
S, Onners B, Tartakovsky I, Nemunaitis J, Le D, Sugar E, Hege K, Jaffee
E. Allogeneic granulocyte macrophage colony-stimulating factor-secreting
tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic
pancreatic cancer: a pilot study of safety, feasibility, and immune activation.
Clin Cancer Res. 2008 Mar 1;14(5):1455-63. 4. Rudin CM, Liu W, Desai A, Karrison T, Jiang X,
Janisch L, Das S, Ramirez J, Poonkuzhali B, Schuetz E, Fackenthal DL,
Chen P, Armstrong DK, Brahmer JR, Fleming GF, Vokes EE, Carducci MA, Ratain
MJ. Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity.
J Clin Oncol. 2008 Mar 1;26(7):1119-27. 5. Wagner-Johnston ND, Ambinder RF. Blood
and marrow transplant for lymphoma patients with HIV/AIDS. Curr Opin Oncol.
2008 Mar;20(2):201-5. Review. 1. Jimeno A, Messersmith WA, Lee CK, Ma WW, Laheru
D, Donehower RC, Baker SD, Hidalgo M. Phase I study of troxacitabine administered
by continuous infusion in subjects with advanced solid malignancies. Ann
Oncol. 2008 Feb;19(2):374-9. 2. Li L, Piloto O, Nguyen HB, Greenberg K, Takamiya
K, Racke F, Huso D, Small D. Knock-in of an internal tandem duplication
mutation into murine FLT3 confers myeloproliferative disease in a mouse
model. Blood. 2008 Feb 1; [Epub ahead of print] 3. Piantadosi S. Rigor in monitoring clinical trials
is ethical. J Clin Oncol. 2008 Feb 1;26(4):683-5. 4. Wolff AC, Berry D, Carey LA, Colleoni M, Dowsett
M, Ellis M, Garber JE, Mankoff D, Paik S, Pusztai L, Smith ML, Zujewski
J. Research issues affecting preoperative systemic therapy for operable
breast cancer. J Clin Oncol. 2008 Feb 10;26(5):806-13. Review. 1. Abukhdeir AM, Vitolo
MI, Argani P, De Marzo AM, Karakas B, Konishi H, Gustin 2. Aggarwal S, Brennen WN, Kole TP, Schneider E,
Topaloglu O, Yates M, Cotter RJ, 3. Bechan GI, Meeker AK, Marzo AM, Racke F, Jaffe
R, Sugar E, Arceci RJ.Telomere length shortening in Langerhans cell histiocytosis.
Br J Haematol. 2007 Dec 19; [Epub ahead of print] 4. Griffiths EA, Gore SD.DNA methyltransferase and
histone deacetylase inhibitors in the treatment of myelodysplastic syndromes.
Semin Hematol. 2008 Jan;45(1):23-30. 5. Matsui W, Wang Q, Barber JP, Brennan S,
Smith BD, Borrello I, McNiece I, Lin 1. Antonarakis ES, Blackford
AL, Garrett-Mayer E, Eisenberger MA. Survival in men with nonmetastatic
prostate cancer treated with hormone therapy: a quantitative systematic
review. J Clin Oncol. 2007 Nov 1;25(31):4998-5008. Review. 2. Lo AK, To KF, Lo KW, Lung RW, Hui JW, Liao G,
Hayward SD. Modulation of LMP1 protein expression by EBV-encoded microRNAs.
Proc Natl Acad Sci U S A. 2007 Oct 9;104(41):16164-9. Epub 2007 Oct 2. 3. Mirmonsef P, Tan G, Zhou G, Morino T, Noonan
K, Borrello I, Levitsky HI. Escape from suppression: tumor-specific effector
cells outcompete regulatory T cells following stem cell transplantation.
Blood. 2007 Dec 6; [Epub ahead of print] 4. Pardoll DM. Building the bionic T cell.
Nat Med. 2007 Dec;13(12):1411-3. No abstract available. 1. Friedman AD. Normal
and malignant hematopoiesis. Oncogene. 2007 Oct 15;26(47):6686. 2. Friedman AD.Transcriptional control of granulocyte
and monocyte development. Oncogene. 2007 Oct 15;26(47):6816-28. 3. Lauring J, Abukhdeir AM, Konishi H, Garay JP,
Gustin JP, Wang Q, Arceci RJ, Matsui W, Park BH. The multiple myeloma-associated
MMSET gene contributes to cellular adhesion, clonogenic growth, and tumorigenicity.
Blood. 2007 Oct 17; [Epub ahead of print] 4. Platz EA. Epidemiologic musing on statin
drugs in the prevention of advanced prostate cancer. Cancer Epidemiol
Biomarkers Prev. 2007 Nov 2; [Epub ahead of print] 1. Basch EM, Somerfield MR, Beer TM, Carducci
MA, Higano CS, Hussain MH, Scher HI. American Society of Clinical Oncology
endorsement of the cancer care Ontario Practice Guideline on nonhormonal
therapy for men with metastatic hormone-refractory (castration-resistant)
prostate cancer. J Clin Oncol. 2007 Oct 9; [Epub ahead of print] 2. Bastian PJ, Palapattu GS, Yegnasubramanian S,
Lin X, Rogers CG, Mangold LA, Trock B, Eisenberger M, Partin AW, Nelson
WG. Prognostic value of preoperative serum cell-free circulating DNA in
men with prostate cancer undergoing radical prostatectomy. Clin Cancer
Res. 2007 Sep 15;13(18):5361-5367. 3. Bolanos-Meade J, Garrett-Mayer E, Luznik L, Anders
V, Webb J, Fuchs EJ, Huff CA, Matsui W, Borrello IM, Brodsky R, Kasamon
YL, Swinnen LJ, Flinn IW, Ambinder RF, Jones RJ, Hess AD, Vogelsang GB.
Induction of autologous graft-versus-host disease: results of a randomized
prospective clinical trial in patients with poor risk lymphoma. Biol Blood
Marrow Transplant. 2007 Oct;13(10):1185-91. 4. Brandes JC, Carraway H, Herman JG. Optimal primer
design using the novel primer design program: MSPprimer provides accurate
methylation analysis of the ATM promoter. Oncogene. 2007 Sep 13;26(42):6229-37.
5. Guo M, House MG, Suzuki H, Ye Y, Brock MV, Lu
F, Liu Z, Rustgi AK, Herman JG. Epigenetic silencing of CDX2 is a feature
of squamous esophageal cancer. Int J Cancer. 2007 Sep 15;121(6):1219-26. 6. Harris TJ, Grosso JF, Yen HR, Xin H, Kortylewski
M, Albesiano E, Hipkiss EL, Getnet D, Goldberg MV, Maris CH, Housseau
F, Yu H, Pardoll DM, Drake CG. Cutting edge: An in vivo requirement for
STAT3 signaling in TH17 development and TH17-dependent autoimmunity. 7. Hucl T, Brody JR, Gallmeier E, Iacobuzio-Donahue
CA, Farrance IK, Kern SE. High cancer-specific expression of mesothelin
(MSLN) is attributable to an upstream enhancer containing a transcription
enhancer factor dependent MCAT motif. Cancer Res. 2007 Oct 1;67(19):9055-65. 8. Jimeno A, Daw NC, Amador ML, Cusatis G, Kulesza
P, Krailo M, Ingle AM, Blaney SM, Adamson P, Hidalgo M; Children's Oncology
Group. Analysis of biologic surrogate markers from a Children's Oncology
Group Phase I trial of gefitinib in pediatric patients with solid tumors.
Pediatr Blood Cancer. 2007 Sep;49(3):352-7. 9. Kern SE, Shibata D. The fuzzy math of solid tumor
stem cells: a perspective. Cancer Res. 2007 Oct 1;67(19):8985-8. 10. Lin TL, Vala MS, Barber JP, Karp JE, Smith BD,
Matsui W, Jones RJ. Induction of acute lymphocytic leukemia differentiation
by maintenance therapy. Leukemia. 2007 Sep;21(9):1915-20. 11. Liu J, Martin HJ, Liao G, Hayward SD. The Kaposi's
sarcoma-associated herpesvirus LANA protein stabilizes and activates c-Myc.
J Virol. 2007 Oct;81(19):10451-9. 12. Nava-Parada P, Emens LA. GV-1001, an injectable
telomerase peptide vaccine for the treatment of solid cancers. Curr Opin
Mol Ther. 2007 Oct;9(5):490-7. 13. Ryu B, Kim DS, Deluca AM, Healey MA, Dunlap
S, Fackler MJ, Herman J, Alani RM. Id1 expression is transcriptionally
regulated in radial growth phase melanomas. Int J Cancer. 2007 Oct 15;121(8):1705-9. 14. Zong JC, Arav-Boger R, Alcendor DJ, Hayward
GS. Reflections on the interpretation of heterogeneity and strain differences
based on very limited PCR sequence data from Kaposi's sarcoma-associated
herpesvirus genomes. J Clin Virol. 2007 Sep;40(1):1-8. 15. Zong JC, Kajumbula H, Boto W, Hayward
GS. Evaluation of global clustering patterns and strain variation over
an extended ORF26 gene locus from Kaposi's sarcoma herpesvirus. 1. Friedman AD. C/EBPalpha
induces PU.1 and interacts with AP-1 and NF-kappaB to regulate myeloid
development. Blood Cells Mol Dis. 2007 Jul 30; [Epub ahead of print] 2. Sandler HM, Eisenberger MA. Assessing and treating
patients with increasing prostate specific antigen following radical prostatectomy.
J Urol. 2007 Jul 16; [Epub ahead of print] 1. Howerton MW, Bell
BS, Dodd KW, Berrigan D, Stolzenberg-Solomon R, Nebeling L. School-based
Nutrition Programs Produced a Moderate Increase in Fruit and Vegetable
Consumption: Meta and Pooling Analyses from 7 Studies. J Nutr Educ Behav.
2007 Jul-Aug;39(4):186-96. 2. Lin TL, Vala MS, Barber JP, Karp JE, Smith BD,
Matsui W, Jones RJ. Induction of acute lymphocytic leukemia differentiation
by maintenance therapy. Leukemia. 2007 Jul 5; [Epub ahead of print] 3. Ryu B, Kim DS, Deluca AM, Alani RM. Comprehensive
expression profiling of tumor cell lines identifies molecular signatures
of melanoma progression. PLoS ONE. 2007 Jul 4;2:e594. 1. Davidson NE. The maturation of medical oncology. Lancet Oncol. 2007
Jun;8(6):457-8. 1. Brown P, McIntyre E, Rau R, Meshinchi S, Lacayo
N, Dahl G, Alonzo TA, Chang M, Arceci RJ, Small D. The incidence and clinical
significance of nucleophosmin mutations in childhood
AML. Blood. 2007 Apr 17; [Epub ahead of print] 2. Casero RA Jr, Marton LJ. Targeting polyamine
metabolism and function in cancer and other hyperproliferative diseases.
Nat Rev Drug Discov. 2007 May;6(5):373-90. 3. Jimeno A, Hallur G, Chan A, Zhang X, Cusatis
G, Chan F, Shah P, Chen R, Hamel E, Garrett-Mayer E, Khan S, Hidalgo M.
Development of two novel benzoylphenylurea sulfur analogues and evidence
that the microtubule-associated protein tau is predictive of their activity
in pancreatic cancer. Mol Cancer Ther. 2007 May 4; [Epub ahead of print]
4. Jimeno A, Rudek MA, Purcell T, Laheru DA, Messersmith
WA, Dancey J, Carducci MA, Baker SD, Hidalgo M, Donehower RC. Phase I
and pharmacokinetic study of UCN-01 in combination with irinotecan in
patients with solid tumors. Cancer Chemother Pharmacol. 2007 Apr 12; [Epub
ahead of print] 5. Nelson WG, Yegnasubramanian S, Agoston AT, Bastian
PJ, Lee BH, Nakayama M, De Marzo AM. Abnormal DNA methylation, epigenetics,
and prostate cancer. Front Biosci. 2007 May 1;12:4254-66. 6. Ohm JE, Baylin SB. Stem cell chromatin patterns:
an instructive mechanism for DNA hypermethylation? Cell Cycle. 2007 May;6(9):1040-3.
Epub 2007 May 28. 7. Zhou S, Kachhap S, Sun W, Wu G, Chuang
A, Poeta L, Grumbine L, Mithani SK, Chatterjee A, Koch W, Westra WH, Maitra
A, Glazer C, Carducci M, Sidransky D, McFate T, Verma A, Califano JA.
Frequency and phenotypic implications of mitochondrial DNA mutations in
human squamous cell cancers of the head and neck. Proc Natl Acad Sci U
S A. 2007 May 1;104(18):7540-5. Epub 2007 Apr 24. 1. Armanios MY, Chen JJ, Cogan JD, Alder JK, Ingersoll
RG, Markin C, Lawson WE, Xie M, Vulto I, Phillips JA 3rd, Lansdorp PM,
Greider CW, Loyd JE. Telomerase mutations in families with idiopathic
pulmonary fibrosis. N Engl J Med. 2007 Mar 29;356(13):1317-26.
2. Jimeno A, Rudek MA, Purcell T, Laheru DA,
Messersmith WA, Dancey J, Carducci MA, Baker SD, Hidalgo M, Donehower
RC. Phase I and pharmacokinetic study of UCN-01 in combination with irinotecan
in patients with solid tumors. Cancer Chemother Pharmacol. 2007 Apr 12;
[Epub ahead of print] 1. Bolanos-Meade J, Vogelsang GB. Montelukast in
chronic graft-versus-host disease: a breath of fresh air? Transplantation.
2007 Mar 15;83(5):527-8. No abstract available. 2. Fu DX, Tanhehco YC, Chen J, Foss CA, Fox JJ,
Lemas V, Chong JM, Ambinder RF, Pomper MG. Virus-associated tumor imaging
by induction of viral gene expression. Clin Cancer Res. 2007 Mar 1;13(5):1453-8.
3. Gallmeier E, Hucl T, Brody JR, Dezentje DA, Tahir
K, Kasparkova J, Brabec V, Bachman KE, Kern SE. High-throughput screening
identifies novel agents eliciting hypersensitivity in Fanconi pathway-deficient
cancer cells. Cancer Res. 2007 Mar 1;67(5):2169-77. 4. Hann CL, Rudin CM. Fast, hungry and unstable:
finding the Achilles' heel of small-cell lung cancer. Trends Mol Med.
2007 Feb 24; [Epub ahead of print] 5. Jimeno A, Kulesza P, Wheelhouse J, Chan A, Zhang
X, Kincaid E, Chen R, Clark DP, Forastiere A, Hidalgo M. Dual EGFR and
mTOR targeting in squamous cell carcinoma models, and development of early
markers of efficacy. Br J Cancer. 2007 Mar 6; [Epub ahead of print] 6. Jimeno A, Rubio-Viqueira B, Amador ML, Grunwald
V, Maitra A, Iacobuzio-Donahue C, Hidalgo M. Dual mitogen-activated protein
kinase and epidermal growth factor receptor inhibition in biliary and
pancreatic cancer. Mol Cancer Ther. 2007 Mar;6(3):1079-88. 7. Klein AP, de Andrade M, Hruban RH, Bondy M, Schwartz
AG, Gallinger S, Lynch 8. Peacock CD, Wang Q, Gesell GS, Corcoran-Schwartz
IM, Jones E, Kim J, Devereux WL, Rhodes JT, Huff CA, Beachy PA, Watkins
DN, Matsui W. Hedgehog signaling maintains a tumor stem cell compartment
in multiple myeloma. Proc Natl Acad Sci U S A. 2007 Mar 6;104(10):4048-53.
Epub 2007 Feb 27. 9. Pledgie-Tracy A, Sobolewski MD, Davidson NE.
Sulforaphane induces cell type-specific apoptosis in human breast cancer
cell lines. Mol Cancer Ther. 2007 Mar;6(3):1013-21. Epub 2007 Mar 5. 10. Williams SA, Merchant RF, Garrett-Mayer E, Isaacs
JT, Buckley JT, Denmeade SR. A prostate-specific antigen-activated channel-forming
toxin as therapy for prostatic disease. 1. Georgantas RW 3rd, Hildreth R, Morisot S, Alder
J, Liu CG, Heimfeld S, Calin GA, Croce CM, Civin CI. CD34+ hematopoietic
stem-progenitor cell microRNA expression and function: A circuit diagram
of differentiation control. Proc Natl Acad Sci U S A. 2007 Feb 9; [Epub
ahead of print] 2. Gillison ML. Current topics in the epidemiology
of oral cavity and oropharyngeal cancers. Head Neck. 2007 Jan 17; [Epub
ahead of print] 3. Kasamon YL. Blood or marrow transplantation for
mantle cell lymphoma. Curr Opin Oncol. 2007 Mar;19(2):128-35. 4. Walczak JR, Carducci MA. Prostate cancer: a practical
approach to current management of recurrent disease. Mayo Clin Proc. 2007
Feb;82(2):243-9. 5. Zhou G, Levitsky HI. Natural regulatory T cells
and de novo-induced regulatory T cells contribute independently to tumor-specific
tolerance. J Immunol. 2007 Feb 15;178(4):2155-62. 1. Diehl F, Diaz LA Jr. Digital quantification of
mutant DNA in cancer patients. Curr Opin Oncol.
2007 Jan;19(1):36-42. 2. Gallmeier E, Kern SE. Targeting Fanconi Anemia/BRCA2
Pathway Defects in Cancer: The Significance of Preclinical Pharmacogenomic
Models. Clin Cancer Res. 2007 Jan 1;13(1):4-10. 3. Gillison ML, Chen R, Goshu E, Rushlow D, Chen
N, Banister C, Creek KE, Gallie BL. Human retinoblastoma is not caused
by known pRb-inactivating human DNA tumor viruses. Int J Cancer. 2007
Jan 4; [Epub ahead of print] 4. Hayward GS, Zong JC. Modern evolutionary history
of the human KSHV genome. Curr Top Microbiol Immunol. 2007;312:1-42. Review.
5. Howerton MW, Gibbons MC, Baffi CR, Gary TL, Lai
GY, Bolen S, Tilburt J, Tanpitukpongse TP, Wilson RF, Powe NR, Bass EB,
Ford JG. Provider roles in the recruitment of underrepresented populations
to cancer clinical trials. Cancer. 2007 Jan 2; [Epub ahead of print] 6. Hudspeth MP, Raymond GV. Immunopathogenesis of
adrenoleukodystrophy: Current understanding. J Neuroimmunol. 2007 Jan;182(1-2):5-12.
Epub 2006 Nov 27. 7. Jones RJ, Matsui W. Cancer Stem Cells: From Bench
to Bedside. Biol Blood Marrow Transplant. 2007 Jan;13S1:47-52. 8. Kasamon YL, Jones RJ, Wahl RL. Integrating PET
and PET/CT into the Risk-Adapted Therapy of Lymphoma. J Nucl Med. 2007
Jan;48(1_suppl):19S-27S. 9. Messersmith WA, Rudek MA, Baker SD, Zhao M, Collins
C, Colevas AD, Donehower RC, Carducci MA, Wolff AC. Phase I study of continuous
weekly dosing of dimethylamino benzoylphenylurea (BPU) in patients with
solid tumours. Eur J Cancer. 2007 Jan;43(1):78-86. Key words: BPU, solid
tumors 10. Nicholas J. Human herpesvirus 8-encoded
proteins with potential roles in virus-associated neoplasia Front Biosci.
2007 Jan 1;12:265-81. 1. Babbar N, Casero RA Jr. Tumor Necrosis Factor-{alpha}
Increases Reactive Oxygen Species by Inducing Spermine Oxidase in Human
Lung Epithelial Cells: A Potential Mechanism
for Inflammation-Induced Carcinogenesis. Cancer Res. 2006 Dec 1;66(23):11125-30.
2. Cheong I, Huang X, Bettegowda C, Diaz LA Jr,
Kinzler KW, Zhou S, Vogelstein 3. Gerber DE, Grossman SA, Zeltzman M, Parisi MA,
Kleinberg L. The impact of thrombocytopenia from temozolomide and radiation
in newly diagnosed adults with high-grade gliomas. Neuro-oncol. 2006 Nov
15; [Epub ahead of print] 4. Hudspeth MP, Raymond GV. Immunopathogenesis of
adrenoleukodystrophy: Current understanding. J Neuroimmunol. 2006 Nov
22; [Epub ahead of print] 5. Williams SA, Singh P, Isaacs JT, Denmeade SR.
Does PSA play a role as a promoting agent during the initiation and/or
progression of prostate cancer? Prostate. 2006 Dec 1; [Epub ahead of print]
1. Carducci MA, Jimeno A. Targeting bone metastasis
in prostate cancer with endothelin receptor antagonists. Clin Cancer Res.
2006 Oct 15;12(20 Pt 2):6296s-6300s. 2. Guo M, House MG, Akiyama Y, Qi Y, Capagna D,
Harmon J, Baylin SB, Brock MV, Herman JG. Hypermethylation of the GATA
gene family in esophageal cancer. Int J Cancer. 2006 Nov 1;119(9):2078-83.
3. Matsui WH, Brodsky RA, Smith BD, Borowitz MJ,
Jones RJ. Reply to 'Quantification of marrow CD34+ cells: an important
tool for distinguishing between hypoplastic myelodysplastic syndromes
and aplastic anemia' by A Orazi. Leukemia. 2006 Nov;20(11):2041-2. Epub
2006 Sep 14. No abstract available. 4. Messersmith WA, Rudek MA, Baker SD, Zhao M, Collins
C, Colevas AD, Donehower RC, Carducci MA, Wolff AC. Phase I study of continuous
weekly dosing of dimethylamino benzoylphenylurea (BPU) in patients with
solid tumours. Eur J Cancer. 2006 Nov 2; [Epub ahead of print] 5. Stearns V. Raloxifene and tamoxifen had similar
efficacy for preventing invasive breast cancer in women at increased risk.
ACP J Club. 2006 Nov-Dec;145(3):72. 6. Stearns V, Schneider B, Henry NL, Hayes
DF, Flockhart DA. Breast cancer treatment and ovarian failure: risk factors
and emerging genetic determinants. Nat Rev Cancer. 2006 Nov;6(11):886-93.
Epub 2006 Oct 12. 1. Armstrong DK, Brady MF. Intraperitoneal therapy
for ovarian cancer: a treatment ready for prime
time. J Clin Oncol. 2006 Oct 1;24(28):4531-3. No abstract available. 2. Brody JR, Hucl T, Gallmeier E, Winter JM, Kern
SE, Murphy KM. Genomic copy number changes affecting the thymidylate synthase
(TYMS) gene in cancer: a model for patient classification to aid fluoropyrimidine
therapy. Cancer Res. 2006 Oct 1;66(19):9369-73. 3. Chen D, Nicholas J. Structural requirements for
gp80 independence of human herpesvirus 8 interleukin-6 (vIL-6) and evidence
for gp80 stabilization of gp130 signaling complexes induced by vIL-6.
J Virol. 2006 Oct;80(19):9811-21. 4. Matsui WH, Brodsky RA, Smith BD, Borowitz MJ,
Jones RJ. Reply to 'Quantification of marrow CD34+ cells: an important
tool for distinguishing between hypoplastic myelodysplastic syndromes
and aplastic anemia' by A Orazi. Leukemia. 2006 Sep 14; [Epub ahead of
print] 5. Stearns V, Schneider B, Henry NL, Hayes DF, Flockhart
DA. Breast cancer treatment and ovarian failure: risk factors and emerging
genetic determinants. Nat Rev Cancer. 2006 Oct 12; [Epub ahead of print]
6. Wu X, Chen H, Parker B, Rubin E, Zhu T, Lee JS,
Argani P, Sukumar S. HOXB7, a homeodomain protein, is overexpressed in
breast cancer and confers epithelial-mesenchymal transition. Cancer Res.
2006 Oct 1;66(19):9527-34. 7. Zahnow CA. ErbB receptors and their ligands
in the breast. Expert Rev Mol Med. 2006 Sep 20;8(23):1-21. 1. Abukhdeir AM, Blair BG, Brenner K, Karakas B,
Konishi H, Lim J, Sahasranaman V, Huang Y, Keen J, Davidson N, Vitolo
MI, Bachman KE, Park BH. Physiologic estrogen receptor
alpha signaling in non-tumorigenic human mammary epithelial cells. Breast
Cancer Res Treat. 2006 Sep;99(1):23-33. 2. Carducci MA, Musib L, Kies MS, Pili R, Truong
M, Brahmer JR, Cole P, Sullivan R, Riddle J, Schmidt J, Enas N, Sinha
V, Thornton DE, Herbst RS. Phase I dose escalation and pharmacokinetic
study of enzastaurin, an oral protein kinase C beta inhibitor, in patients
with advanced cancer. J Clin Oncol. 2006 Sep 1;24(25):4092-9. 3. Drake CG. Basic overview of current immunotherapy
approaches in urologic malignancy. Urol Oncol. 2006 Sep-Oct;24(5):413-8.
4. Georgantas RW 3rd, Bohana-Kashtan O, Civin CI.
Ex vivo soluble fas ligand treatment of donor cells to selectively reduce
murine acute graft versus host disease. Transplantation. 2006 Aug 27;82(4):471-8.
5. Grossman SA, Carson KA, Batchelor TT, Lesser
G, Mikkelsen T, Alavi JB, Phuphanich S, Hammour T, Fisher JD, Supko JG.
The effect of enzyme-inducing antiseizure drugs on the pharmacokinetics
and tolerability of procarbazine hydrochloride. Clin Cancer Res. 2006
Sep 1;12(17):5174-81. 6. Hu F, Nicholas J. Signal transduction by human
Herpesvirus 8 viral Interleukin-6 (vIL-6) is modulated by the non-signaling
gp80 subunit of the IL-6 receptor complex and is distinct from signaling
induced by human IL-6. J Virol. 2006 Sep 6 [Epub ahead of print]. 7. Juergens R, Brahmer J, Ettinger D. Gemcitabine
and vinorelbine in recurrent advanced non-small cell lung cancer: sequence
does matter. Cancer Chemother Pharmacol. 2006 Aug 26; [Epub ahead of print]
8. Powell JD. The induction and maintenance of T
cell anergy. Clin Immunol. 2006 Sep;120(3):239-46. 9. Rudek MA, Zhao M, He P, Messersmith WA, Baker
SD. Validation and implementation of a liquid chromatography/tandem mass
spectrometry assay to quantitate ABT-751, ABT-751 glucuronide, and ABT-751
sulfate in human plasma for clinical pharmacology studies. J Pharm Biomed
Anal. 2006 Sep 18;42(2):253-60. 10. Zhao M, Rudek MA, Mnasakanyan A, Hartke
C, Pili R, Baker SD. A liquid chromatography/tandem mass spectrometry
assay to quantitate MS-275 in human plasma. 1. Brown P, Levis M,
McIntyre E, Griesemer M, Small D. Combinations of the FLT3 inhibitor CEP-701
and chemotherapy synergistically kill infant and childhood MLL-rearranged
ALL cells in a sequence-dependent manner. Leukemia. 2006 Aug;20(8):1368-76.
Epub 2006 Jun 8. 2. Ettinger DS, Bepler
G, Bueno R, Chang A, Chang JY, Chirieac LR, D'Amico TA, Demmy TL, Feigenberg
SJ, Grannis FW Jr, Jahan T, Jahanzeb M, Kessinger A, Komaki R, Kris MG,
Langer CJ, Le QT, Martins R, Otterson GA, Robert F, Sugarbaker DJ, Wood
DE; National Comprehensive Cancer Network (NCCN). Non-small cell lung
cancer clinical practice guidelines in oncology. J Natl Compr Canc Netw.
2006 Jul;4(6):548-82. 3. Gardner ER, Burger H, van Schaik RH, van Oosterom
AT, de Bruijn EA, Guetens G, Prenen H, de Jong FA, Baker SD, Bates SE,
Figg WD, Verweij J, Sparreboom A, Nooter K. Association of enzyme and
transporter genotypes with the pharmacokinetics of imatinib. Clin Pharmacol
Ther. 2006 Aug;80(2):192-201. 4. Gibson MK, Forastiere AA. Reassessment of the
role of induction chemotherapy for head and neck cancer. Lancet Oncol.
2006 Jul;7(7):565-74. Review. 5. Guo M, House MG, Akiyama Y, Qi Y, Capagna D,
Harmon J, Baylin SB, Brock MV, Herman JG. Hypermethylation of the GATA
gene family in esophageal cancer. Int J Cancer. 2006 Jul 5; [Epub ahead
of print] 6. Guo M, Ren J, House MG, Qi Y, Brock MV, Herman
JG. Accumulation of promoter methylation suggests epigenetic progression
in squamous cell carcinoma of the esophagus. Clin Cancer Res. 2006 Aug
1;12(15):4515-22. 7. Johnson BE, Crawford J, Downey RJ, Ettinger DS,
Fossella F, Grecula JC, Jahan T, Kalemkerian GP, Kessinger A, Koczywas
M, Langer CJ, Martins R, Marymont MH, Niell HB, Ramnath N, Robert F, Williams
CC Jr; National Comprehensive Cancer Network (NCCN). Small cell lung cancer
clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2006
Jul;4(6):602-22. 8. Kim KT, Levis M, Small D. Constitutively activated
FLT3 phosphorylates BAD partially through Pim-1. Br J Haematol. 2006 Jul
26; [Epub ahead of print] 9. Ndovi TT, Choi L, Caffo B, Parsons T, Baker S,
Zhao M, Rohde C, Hendrix CW. Quantitative assessment of seminal vesicle
and prostate drug concentrations by use of a noninvasive method. Clin
Pharmacol Ther. 2006 Aug;80(2):146-58. 10. Pfister DG, Laurie SA, Weinstein GS, Mendenhall
WM, Adelstein DJ, Ang KK, Clayman GL, Fisher SG, Forastiere AA, Harrison
LB, Lefebvre JL, Leupold N, List MA, O'Malley BO, Patel S, Posner MR,
Schwartz MA, Wolf GT. American Society of Clinical Oncology clinical practice
guideline for the use of larynx-preservation strategies in the treatment
of laryngeal cancer. J Clin Oncol. 2006 Aug 1;24(22):3693-704. Epub 2006
Jul 10. 12. Sciubba DM, Mavinkurve GG, Gailloud P, Garonzik
IM, Recinos PF, McGirt MJ, Woodworth GF, Witham T, Khavkin Y, Gokaslan
ZL, Wolinsky JP. Preoperative imaging of cervical spine hemangioblastomas
using three-dimensional fusion digital subtraction angiography: report
of two cases. J Neurosurg Spine. 2006 Jul;5(1):96-100. 13. Wong AS, Soo RA, Lu JJ, Loh KS, Tan KS, Hsieh
WS, Shakespeare TP, Chua ET, Lim HL, Goh BC. Paclitaxel, 5-fluorouracil
and hydroxyurea concurrent with radiation in locally advanced nasopharyngeal
carcinoma. Ann Oncol. 2006 Jul;17(7):1152-1157. Epub 2006 May 9. 1. Bose R, Molina H, Patterson AS, Bitok JK, Periaswamy
B, Bader JS, Pandey A, Cole PA. Phosphoproteomic analysis of Her2/neu
signaling and inhibition. Proc Natl Acad Sci U S A. 2006 Jun 27;103(26):9773-9778.
Epub 2006 Jun 19. 2. Brandes JC, Herman JG, Hodge DR, Farrar WL. p53
Expression after Treatment with Zebularine Is Not Due to Demethylation.
Cancer Res. 2006 Jul 1;66(13):6892-3. 4. Diehl F, Li M, He Y, Kinzler KW, Vogelstein B,
Dressman D. BEAMing: single molecule PCR on microparticles in water-in-oil
emulsions. Nat Methods. 2006 Jul;3(7):551-9. 7. Guo M, House MG, Akiyama Y, Qi Y, Capagna D,
Harmon J, Baylin SB, Brock MV, Herman JG. Hypermethylation of the GATA
gene family in esophageal cancer. Int J Cancer. 2006 Jul 5; [Epub ahead
of print] 11. Rubio-Viqueira B, Hidalgo M. Targeting mTOR
for cancer treatment. Curr Opin Investig Drugs. 2006 Jun;7(6):501-12.
1. Ettinger DS. Clinical implications of EGFR expression
in the development and progression of solid
tumors: focus on non-small cell lung cancer. Oncologist. 2006 Apr;11(4):358-73.
2. Hess AD, Thoburn CJ. Immune tolerance to self-major
histocompatability complex class II antigens after bone marrow transplantation:
role of regulatory T cells. Biol Blood Marrow Transplant. 2006 May;12(5):518-29.
3. Huff CA, Matsui WH, Douglas Smith B, Jones RJ.
Strategies to eliminate cancer stem cells: Clinical implications. Eur
J Cancer. 2006 Jun;42(9):1293-7. Epub 2006 Apr 27. 4. Karakas B, Weeraratna A, Abukhdeir A, Blair BG,
Konishi H, Arena S, Becker 5. Kern SE, Winter JM. Elegance, silence and nonsense
in the mutations literature for solid tumors. Cancer Biol Ther. 2006 Apr;5(4):349-59.
Epub 2006 Apr 1. 6. Powell JD. The induction and maintenance of T
cell anergy. Clin Immunol. 2006 Mar 30; [Epub ahead of print] 7. Wang D, D'Costa J, Civin CI, Friedman AD. C/EBP{alpha}
directs monocytic commitment of primary myeloid progenitors. Blood 2006
Apr 27; [Epub ahead of print] 1. Abukhdeir AM, Blair BG, Brenner K, Karakas B,
Konishi H, Lim J, Sahasranaman 2. Aggarwal S, Harden JL, Denmeade SR. Synthesis
and screening of a random dimeric peptide library using the one-bead-one-dimer
combinatorial approach. Bioconjug Chem. 2006 Mar-Apr;17(2):335-40. 3. Baker SD, Sparreboom A, Verweij J. Clinical pharmacokinetics
of docetaxel : recent developments. Clin Pharmacokinet. 2006;45(3):235-52.
4. Cope L, Hartman SM, Gohlmann HW, Tiesman JP,
Irizarry RA. Analysis of Affymetrix GeneChip data using amplified RNA.
Biotechniques. 2006 Feb;40(2):165-6, 168, 170. 5. Garrett-Mayer E. The continual reassessment method
for dose-finding studies: a tutorial. Clin Trials. 2006;3(1):57-71. 6. Hallur G, Jimeno A, Dalrymple S, Zhu T, Jung
MK, Hidalgo M, Isaacs JT, Sukumar S, Hamel E, Khan SR. Benzoylphenylurea
sulfur analogues with potent antitumor activity. J Med Chem. 2006 Apr
6;49(7):2357-60. 7. Helzlsouer KJ, Erlinger TP, Platz EA. C-reactive
protein levels and subsequent cancer outcomes: Results from a prospective
cohort study. Eur J Cancer. 2006 Apr;42(6):704-707. Epub 2006 Mar 2. 8. Jimeno A. Race, gender and mutations in the prediction
of anti-EGFR activity. Future Oncol. 2005 Apr;1(2):201-4. 9. Kato Y, Okollie B, Artemov D. Noninvasive 1H/13C
magnetic resonance spectroscopic imaging of the intratumoral distribution
of temozolomide. Magn Reson Med. 2006 Apr;55(4):755-61. 10. Kern SE, Winter JM. Elegance, Silence
and Nonsense in the Mutations Literature for Solid Tumors. Cancer Biol
Ther. 2006 Apr 1;5(4) 1. Baylin SB, Ohm JE. Epigenetic gene silencing
in cancer - a mechanism for early oncogenic
pathway addiction? Nat Rev Cancer. 2006 Feb;6(2):107-16. Review. |
